During the past decade, Nephrology and Dialysis Unit, "G. Bernabeo" Hospital conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Nephrology and Dialysis Unit, "G. Bernabeo" Hospital" are "End Stage Renal Disease" (2 trials), "Diabetes" (1 trials) and "Insulin Resistance" (1 trials). Many other conditions were trialed in "Nephrology and Dialysis Unit, "G. Bernabeo" Hospital" in a lesser frequency.

Most popular intervention types in "Nephrology and Dialysis Unit, "G. Bernabeo" Hospital" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "PD Solution" (1 trials), "PD solution containing L-carnitine" (1 trials), "PD solution containing glucose" (1 trials) and "PD solution containing glucose and L-carnitine" (1 trials). Other intervention names were less common.

The vast majority of trials in "Nephrology and Dialysis Unit, "G. Bernabeo" Hospital" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Nephrology and Dialysis Unit, "G. Bernabeo" Hospital". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Nephrology and Dialysis Unit, "G. Bernabeo" Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Nephrology and Dialysis Unit, "G. Bernabeo" Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".